Investigational Site Number :3760003

Jerusalem 9112001

2 studies enrolling now · 12 studies all time

What they study most

Asthma, Atopic Dermatitis, Bronchiectasis, Chronic Obstructive Pulmonary Disease, Dermatitis Atopic, Heart Failure, Type 2 Diabetes Mellitus

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis — Completed
• A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis — Running, not enrolling
• Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials — Enrolling by invitation
• Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Running, not enrolling
• Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma — Enrolling by invitation
• A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD — Running, not enrolling
• Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma — Completed
• A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis — Completed
• SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients" — Completed
• Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) — Stopped early